Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Generic Drugs International

Teva, Sandoz And Accord Take COVID-19 Action

Apotex Donates Critical Medicines, MedPharm Screens And Beximco Focuses Efforts

  • News

Executive Summary

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Coronavirus COVID-19 Generic Drugs International
Latest Headlines

UK Generic Price Spikes Ease In April

Taking European Biosimilars To The Next Level

'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action

MS Pharma Bags Formycon’s Eylea Biosimilar Rights In MENA

See All
UsernamePublicRestriction

Register

GB149942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By